Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics?
Currently available antihypertensive drugs lower blood pressure through widely different hemodynamic mechanisms. In general, P-blockers tend to produce chronic depression of cardiac output, particularly during exercise,' and consequently may induce reduction of physical endurance during severe work loads.2-4 In contrast, a-blockers, calcium-channel blockers, and angiotensin-converting enzyme (ACE) inhibitors reduce vascular resistance and maintain blood fl~w,~-il but the degree of counteracting reflex tachycardia and the increase in cardiac output vary widely.
The antihypertensive effect of ACE inhibitors is likely mediated largely by withdrawal of the vaso-pressor influences of angiotensin II,i2, l3 although other mechanisms, such as bradykinin potentiation, have been proposed. 141i5 Both angiotensin II withdrawal and bradykinin potentiation result in arteriolar dilatation and the resultant decrease in vascular resistance. Quinapril hydrochloride is an orally active, nonsulfhydryl, nonpeptide ACE inhibitor approved for the treatment of hypertension and congestive heart failure in a number of international markets.16 Clinical studies indicate that quinapril is an effective antihypertensive agent when administered once daily.17-lg This is interesting, inasmuch as the plasma half-life of the active metabolite, quinaprilat, is approximately 2 hours and the effective accumulation half-life (based on urinary excretion) is approximately 3 hours. 2o We investigated cardiac and renal hemodynamic effects of quinapri121 in relation to a stable blood pressure reduction of approximately 10 to 15 mm Hg (compared with placebo) both at home and in the clinic in patients who monitored their own blood pressure, and who had estab- May 1992 American Heart Journal lished diastolic blood pressure at home of greater than 95 mm Hg when untreated (i.e., no "white coat" phenomenon). Here we obtain detailed records from the daily home blood pressure and heart rate measurements of the 10 patients, and we also present individual patient changes in cardiac index and renal blood flow as well as evidence of improved diastolic function.
METHODS
Patients. Ten white men averaging 42 t 3 years (range, 32 to 61 years) with uncomplicated mild to moderate essential hypertension were studied.21 After informed consent was obtained, all antihypertensive medications were discontinued for 3 weeks, and patients were included in the study if they had stable diastolic blood pressures between 95 and 115 mm Hg at home (sitting) and in the outpatient clinic (supine) at the end of this period. One patient was stable on thyroid hormone replacement.
Aside from essential hypertension, no subject had any other acute or chronic illness. All patients were nonsmokers and did not abuse alcohol or drugs. They were urged not to change their dietary or drinking habits during the study period. Protocol. After the initial 3 weeks without antihypertensive treatment, patients were randomly assigned to a double-blind, two-period crossover trial comparing quinapril and placebo. Quinapril, 20 mg, or matching placebo was each given twice daily for 4 weeks. On the last day of each 4-week period, 12 hours after taking the next to last dose of medication, and having fasted for 12 hours (i.e., overnight), patients were admitted to the University of Michigan Clinical Research Center for 4 hours for hemodynamic profiling.
Subjects were placed at supine rest in a quiet room. Baseline blood pressure was measured in the right arm as the average of two readings by a newly calibrated mercury sphygmomanometer, and baseline heart rate was calculated from the average of 20 to 40 beats taken from the ECG tracing. After baseline blood pressure and heart rate were measured, the morning dose of medication (quinapril or placebo) was given. Thereafter, blood pressure and heart rate were measured every half hour throughout for 4 hours, and hemodynamic profiling was performed 2 to 4 hours after the last dose. The echocardiographic and Doppler procedures used in this study are described in detail elsewhere. 22, 23 Plasma clearance of paraaminohippuric acid (PAH), an estimate of effective renal plasma flow, was measured at 3 '/z hours after the administration of the morning dose of placebo or quinapril by a steady-state infusion method.24, 25 A plasma blank was first obtained, after which an intravenous priming dose of 8 mg/kg of PAH was administered over a lo-minute period. PAH was then infused for 1 hour, from 2% to 3% hours after the dose of placebo or quinapril was given, at a rate calculated to achieve a target PAH plasma concentration of 0.02 mg/ml. A single blood sample was drawn for measurement of PAH concentration at the end of the l-hour infusion, and PAH clearance was calculated from the infusion rate and steady-state PAH The study was approved by the Human Subject Review Committee of the University of Michigan.
Statistical analysis. The data were tested for an order of treatment effect. Because none could be found, further analyses compared the quinapril-treatment with the placebo-treatment period, regardless of the order in which they were given. Blood pressure and vascular resistance were postulated to fall; therefore differences in these variables were tested by one-tailed
tests. Other differences were tested by two-tailed parametric tests for single or repeated measurements.
A value of p < 0.05 was considered the limit for statistical significance. Data are presented as means + SE.
RESULTS
Blood pressure.
Blood pressure was significantly lowered by treatment with quinapril compared with placebo. As shown in Fig. 1 , A and B, home blood pressures, both systolic and diastolic, averaged 10 to 15 mm Hg lower for those receiving quinapril compared with placebo (p < 0.001, analysis of variance) for most of the 4-week period. However, at the beginning and end of each treatment period, differences leveled out because of the crossover design and slightly different lengths of individual treatment periods. Blood pressure recordings and differences between quinapril and placebo were of the same levels and magnitudes in the clinic as those measured by the patients at home. Also, the single dose of quinapril administered 12 hours after the last long-term drug dose had no discernible additional effect on blood pressure at the expected peak pharmacodynamic action, that is, 3 hours after the dose of quinapril.
Heart rate and plasma catecholamines.
There was no significant difference in home heart rate between the quinapril and placebo treatments ( Fig. 1, C quinapril and placebo (NS).
for placebo and quinapril, respectively; p < 0.01). Left ventricular wall stress decreased significantly with quinapril compared with placebo (149 + 9 versus 170 + 8 ~10~ dynes/cm2, p < 0.01). Previously unanalyzed records of the Doppler sonography showed improvements in diastolic function: the peak E/A ratio increased in 8 of the 10 patients, and the overall increase was significant (from 1.12 + 0.11 to 1.31 f 0.10 arbitrary units for placebo and quinapril, respectively; p < 0.02).
Renal hemodynamics.
Renal blood flow remained unchanged in the 10 patients (907 + 36 vs 896 + 28 ml/min for quinapril and placebo, respectively) (Fig.  3) . However, renal vascular resistance was significantly (p < 0.05) lower when taking quinapril (12.2 f 0.8 arbitrary units) compared with placebo (13.6 t 0.6), which suggests that reduced renal vascular resistance may partly explain the reduction in total vascular resistance during treatment with quinapril.
Glomerular filtration rate and filtration fraction remained unchanged, which resulted in a lower glomerular filtration pressure. DISCUSSION 
ACE inhibition
induces a decrease in total and renal vascular resistance without changing cardiac output g-11,27-29 Quinapril lowers blood pressure by the same mechanism.
The changes induced by quinapril differ from the reduced cardiac output and The degree of counteracting reflex tachycardia and the increase in cardiac output vary widely with vasodilator therapy of hypertension.5-1' Even though quinapril produced a substantial fall in blood pressure, heart rate and plasma catecholamines remained virtually unchanged. The same observation has been made for captopril,g, lo, 27-2g, 33 enalapril,ll, 34 and lisinopril,34 and appears to be a class effect of ACE inhibition. It has been shown that with captopril,35a 36 enalapril,37$38 and lisinopril,38 the absence of reflex tachycardia with blood pressure reduction may be related to increased parasympathetic tone. It is likely that the absence of tachycardia with quinapril has a similar mechanism.
The reduction in systemic vascular resistance by long-term ACE inhibition appears to be unevenly distributed in the circulation. Lisinopril did not change the splanchnic vascular resistance,3g and we2r did not detect a significant decrease in forearm vascular resistance with quinapril.
However, captopri12s* 2gs 40, 41 and lisinopri13' and in the present study quinapril reduced renal vascular resistance. This Volume 123
Number 5 may be explained by the particularly pronounced vasoconstricting action of angiotensin II in the renal circulation,42> 43 especially in patients with essential hypertension.44
Long-term treatment of essential hypertension with captopril or enalapril has been associated with no change45, 46 or a relatively small increase2gT 3g, 41 in renal blood flow and unchanged glomerular filtration rate.2g, 3g-41. 45. 46 An increase in renal blood flow may possibly be related to withdrawal of the effect of angiotensin, which is more potent in constricting the efferent than the afferent glomerular arteriole.47 However, a fall in filtration fraction may also indicate a redistribution of renal blood flow to more superficial nephrons known to have a low filtration fraction4s 4g or relate to reduction in glomerular capillary hydraulic pressure. 5o In the present study, the fall in blood pressure and renal vascular resistance was not accompanied by a change in renal plasma flow, glomerular filtration rate, or filtration fraction. Presumably the failure of renal blood flow to increase was caused by a reduction in perfusion pressure. Thus the effect of quinapril on renal function is consistent with intact autoregulation of renal hemodynamics. This conclusion is in agreement with studies in laboratory animals5' in which angiotensin II was not required for renal autoregulation.
We found left ventricular peak systolic wall stress in the same range as reported by others.52 Although we demonstrated a significant reduction in wall stress and, as estimated by the peak E/A ratio, an improvement in diastolic function, we did not find a significant reduction in left ventricular mass. ACE inhibition may decrease left ventricular mass.53 However, a 4-week treatment period may be too brief to detect such changes and longer studies will be required.
Oral administration of quinapril 12 hours after a previous dose produced no significant acute hemodynamic effects. This may seem somewhat surprising, because the plasma half-life of the active metabolite, quinaprilat, is approximately 2 hours and the effective accumulation is 3 hours after a single 20 mg dose54 and quinaprilat is minimally detectable in plasma 8 to 12 hours after administration.54, 55 However, quinapril-induced plasma ACE inhibition is almost complete at 8 to 12 hours and is still depressed by 25 % at 24 hours after administration, suggesting tight binding of the drug to the enzyme.55 In addition, quinaprilat55 has been demonstrated to inhibit tissue ACE even after plasma ACE activity has returned to near-normal levels. Although the precise contribution of tissue angiotensin II production to hypertension is not yet defined, the antihypertensive effect of ACE inhibition more closely parallels tissue than 
